Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 111Magnetic Resonance Spectroscopy 88Carboplatin 58pembrolizumab 57Biopsy 56Cisplatin 51Nivolumab 46Paclitaxel 39Radiotherapy 38Cyclophosphamide 38Gemcitabine 33Dexamethasone 31Radiation 30Bevacizumab 30atezolizumab 27Pemetrexed 27Etoposide 27olaparib 24Lenalidomide 24Doxorubicin 23X-Rays 22Vincristine 22Prednisone 22Leucovorin 22Immunoglobulin G 22Docetaxel 22Disulfides 22venetoclax 21durvalumab 21Rituximab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × pazopanib × 30 days × Clear all
NCT01575548 2026-05-29

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

National Cancer Institute (NCI)

Phase 3 Active not recruiting
129 enrolled 11 charts
Genitourinary

Carcinoma, Renal Cell

NCT01841736 2026-05-29

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
171 enrolled 15 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡